Michael Serbin, PharmD

Director, HEOR
Neurocrine Biosciences, Inc.

Poster(s):

• (59) Indirect treatment comparison for early efficacy of VMAT2 inhibitors for tardive dyskinesia and chorea associated with Huntington’s disease
  Wednesday, October 29, 2025